Both in Biotechnology
Vir Biotechnology vs Recursion Pharmaceuticals
Over the past year VIR returned +96.4% and RXRX returned −29.6%; their daily moves had a correlation of 0.48.
VIR +96.4% RXRX −29.6%Growth of $1, one year, split-adjusted
| Metric | VIR | RXRX |
|---|---|---|
| Price | $11.00 | $3.83 |
| Market cap | $1.86B | $2.29B |
| Today | −2.65% | −4.96% |
| 1 month | −1.5% | −7.0% |
| 6 months | +8.1% | +8.8% |
| Year to date | +82.4% | −6.4% |
| 1 year | +85.5% | −32.2% |
| Revenue growth (YoY) | +19582.5% | −60.1% |
| Gross margin | 100.0% | −49.8% |
| Net margin | 33.5% | −1708.0% |
| P/E (TTM) | — | — |
| Price / sales | 6.1× | 41.7× |
| Net cash | $532.7M | $531.5M |
| Dividend yield | — | — |
| Volatility (60d) | 51.4% | 95.1% |
| Short % of float | 12.3% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).